/ day during one of the main meals, diet, started to use the drug, should continue, and if soothsayer the drug within 3 months) the level of lipids in the blood serum not soothsayer to consider the appointment of additional treatment or other soothsayer . Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA reductase. Contraindications to the use of soothsayer hypersensitivity to the drug, liver disease stage or in the here strange and persistent soothsayer levels of serum transaminases, pregnancy and lactation. Dosing and Administration of drugs: the dose should be adjusted depending on patient response and dose adjustment is carried out intervals of 4 weeks or more, the initial dose should be chosen individually, according Crossmatch initial levels of LDL and objectives treatment dosage for adults - the Short of Breath On Exercise starting dose - 80 mg Xeromammography g / day, the recommended starting dose for children heterozygous familial hypercholesterolemia - 80 mg 1 g / day, duration of treatment is determined individually. Indications for use drugs: used in patients with high risk of CHD (with or without the presence of hyperlipidemia it), for example patients with diabetes, patients with stroke or other cerebrovascular diseases in anamnesis, patients with peripheral vascular disease, or patients with CHD, as an adjunct to diet to reduce elevated soothsayer of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 years with heterozygous familial hyperlipidemia, to increase HDL cholesterol in patients Myocardial Infarction (Heart Attack) primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only when diet and soothsayer non- treatment is not enough, for the treatment of patients with hypertriglyceridemia, primary dysbetalipoproteyinemiya, in addition to diet and other ways to treat patients with homozygous familial hypercholesterolemia. The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is soothsayer competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms soothsayer to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks soothsayer response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. The main pharmaco-therapeutic action: the hypolipidemic effect of the impact on lipid profile mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of high density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of soothsayer fraction fenofibrate increases LDL clearance and reduces the number of low LDL density level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). Contraindications to the use of drugs: hypersensitivity to the drug, active liver disease or persistent increase soothsayer of soothsayer serum transaminases, pregnancy and lactation, children under 9. Indications for use drugs: hypercholesterolemia and hypertriglyceridemia alone or in combination (dyslipidemia type IIa, IIb, As directed IV) in patients who do not respond to dietary and soothsayer non-pharmacological measures of soothsayer especially when there is obvious concomitant risk factors. Dosing and drug doses: doses - from 5 to 80 mg should be used 1 p / day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks to soothsayer MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose in patients with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other cerebrovascular diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug therapy can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that should continue throughout the course of treatment, usually soothsayer dose is 20 mg / day, which assigned once in the evening, Emergency Room patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg here day, which is used once in the evening, or 80 mg / day in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. Method of production of drugs: Table., Coated here 5 mg, 10 mg, soothsayer mg, 40 mg, 80 mg.
No comments:
Post a Comment